Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
2013; Elsevier BV; Volume: 122; Issue: 7 Linguagem: Inglês
10.1182/blood-2013-01-481341
ISSN1528-0020
AutoresJohn Radford, Andrew Davies, Guillaume Cartron, Franck Morschhauser, Gilles Salles, Robert Marcus, Michael Wenger, Guiyuan Lei, Elisabeth Wassner-Fritsch, Umberto Vitolo,
Tópico(s)Monoclonal and Polyclonal Antibodies Research
ResumoKey Points Obinutuzumab is a novel type II anti-CD20 monoclonal antibody under early-stage clinical investigation. Obinutuzumab plus CHOP or FC has an acceptable safety profile and is effective in relapsed/refractory follicular lymphoma.
Referência(s)